DOE land transfer puts company on-track for domestic Mo-99 facility

The U.S. Department of Energy (DOE) recently transferred land in Oak, Ridge Tennessee to Coquí Radio Pharmaceuticals, pushing the company closer to establishing a domestic production of Molybdenum-99 (Mo-99), an isotope used in many molecular imaging exams.

In addition to the 206 acres of land, Coquí will receive research support from surrounding national laboratories, including Oak Ridge National Laboratory and the Y-12 National Security Complex, according to a statement from the company.

The proposed facility is expected by be fully operational by 2025 and will produce a variety of medical isotopes, but Mo-99 will be its central focus.

“This research partnership is critical and supports our efforts to obtain Nuclear Regulatory Commission and Food and Drug Administration approvals for the facility. The sooner we can begin producing U.S.-made Mo-99, the sooner we can minimize our dependency on foreign imports to meet critical U.S. medical needs,” said Carmen I. Bigles, founder and CEO of Coquí.

Mo-99 shortages are a well-known concern, with the most recent episode taking place during November 2018. That supply issue consisted of a planned 11-day shutdown of an Australian reactor, and coincided with an ongoing problem with the NTP facility in South Africa.

In February, the Department of Energy’s National Nuclear Security Administration (NNSA) announced it had appropriated up to $15 million in funding for four U.S. companies targeting the domestic production of Mo-99. Coquí Radio Pharmaceuticals was not on that list.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

Trimed Popup
Trimed Popup